Summary of ASP Isotopes (ASPI) Conference Call - July 17, 2025 Company Overview - **Company Name**: ASP Isotopes Inc. (ASPI) - **Industry**: Advanced materials, specifically isotope production for medical, semiconductor, and nuclear energy sectors - **Stock Exchange**: NASDAQ Key Points and Arguments Business Structure and Operations - ASP Isotopes operates three verticals: ASP Isotopes, PET Labs, and Quantum Leap Energy [3][4] - **ASP Isotopes**: Focuses on isotope production with three manufacturing facilities in South Africa, currently starting up [3] - **PET Labs**: Leading supplier of fluorinated PET isotopes in South Africa, generating approximately $4 million in annual revenue with a 7% gross margin [4] - **Quantum Leap Energy**: Focuses on nuclear fuels, specifically lithium-six and HALEU, with plans to spin out this segment by October 2025 [5] Acquisition and Financials - ASP Isotopes is acquiring ReneGen, a South African helium producer, which has secured $530 million in committed capital and access to low-cost energy [6][8] - The acquisition aims to create synergies between helium and isotope production, potentially lowering cash production costs by 94% [9] - ASP Isotopes targets over $300 million in EBITDA by 2030 post-spinout of Quantum Leap Energy [10] Market Dynamics - The global isotope production is heavily dominated by Russia, with a lack of domestic production in the U.S. [11] - Helium supply is fragile, with 80% sourced from three countries, leading to price volatility and shortages [12] - The company sees significant growth opportunities in medical isotopes, particularly for cancer treatment, and semiconductor applications [16][25] Technological Advancements - ASP Isotopes employs two main technologies: ASP process and quantum enrichment process, which are more cost-effective and modular compared to traditional methods [15] - The company is focusing on producing isotopes like Uterbium-176 and Zinc-68, which are critical for new oncology drugs and diagnostic markers [18][21] Future Plans and Challenges - Plans to construct additional plants for Gadolinium-160, Zinc-68, and Nickel-64 in South Africa, with quick build times of 2-3 months [43] - A larger ASP plant is planned for Iceland, with a focus on high return on capital projects [44] - The company has faced operational challenges during plant startups but has successfully overcome them [36][38] Government Relations and Funding - ASP Isotopes is in discussions with the U.S. Department of Energy (DOE) for potential funding and support, emphasizing the strategic importance of their operations [50][51] - The company is optimistic about the current U.S. administration's support for bringing their facilities to the U.S. [55] Competitive Landscape - ASP Isotopes does not currently view Hexium as a significant competitor, citing their lack of isotope production capabilities [70] - The company believes its quantum enrichment technology offers a competitive advantage over traditional methods [71] Additional Important Information - The company has a strong relationship with the South African government, facilitating operations and regulatory approvals [7] - ASP Isotopes has a robust balance sheet, with $56 million in cash and additional equity raised to fund high-return projects [46] - The company is exploring partnerships for uranium enrichment facilities in the U.S. and U.K. to expedite market entry [48] This summary encapsulates the key insights from the ASP Isotopes conference call, highlighting the company's strategic direction, market opportunities, and operational challenges.

Core Insights - ASP Isotopes Inc. is advancing its commercial production of isotopes, particularly Silicon-28 and Ytterbium-176, with significant capacity expansions and operational updates [1][4]. Production Updates - Silicon-28 production commenced in late March 2025, achieving an enrichment level of 99% and expected to ship products enriched to at least 99.995% by August 2025. The annual capacity is now projected to exceed 80 kilograms, up from previous estimates of 50 kilograms and initial expectations of 10 kilograms, with a $4 million investment for capacity expansion [2]. - Ytterbium-176 production began in April 2025, reaching an enrichment factor of 52, with plans to ship commercial samples by August 2025. The production process is transitioning to a semi-continuous method to target a production rate of 1 kilogram per annum [3]. Equipment and Facility Developments - The company has received permits to import laser equipment for enriching Nickel-64, Gadolinium-160, and Zinc-68, and is accelerating plans for additional enrichment facilities in South Africa [5]. - The Carbon-14 enrichment plant faced delays due to insufficient feedstock but is now enriching Carbon-12 to 99.99%, with commercial supply expected in August 2025. Demand for Carbon-12 is significantly higher than for Carbon-14, prompting the company to consider expanding capacity [6][7]. Technological Advancements - The company utilizes the Aerodynamic Separation Process (ASP technology) for isotope enrichment, which is believed to offer a cost-effective and efficient method compared to traditional separation techniques [8]. Future Plans - The company plans to spin out its subsidiary Quantum Leap Enrichment in the second half of 2025, targeting October 2025 for completion, and anticipates closing the Renergen acquisition in the third quarter of 2025, pending regulatory approvals [9].

Company Overview - ASP Isotopes Inc. is an advanced materials company focused on developing technology and processes for isotope production across multiple industries [13] - The company employs proprietary technology, the Aerodynamic Separation Process, and aims to produce highly enriched isotopes for healthcare and technology, as well as nuclear energy using Quantum Enrichment technology [13][14] Leadership Appointment - Dr. Ryno Pretorius has been appointed as the Chief Executive Officer of Quantum Leap Energy LLC, a subsidiary of ASP Isotopes, which is focused on developing advanced nuclear fuels [1][5] - Paul Mann will continue as the chairman and CEO of ASP Isotopes and chairman of QLE [2] Dr. Ryno Pretorius' Background - Dr. Pretorius has over 15 years of experience as a chemical engineer, including four years at Necsa, where he gained insights into the nuclear fuel supply chain [3] - He has served as technical director and CEO of Free Radical Process Design, a consulting firm that has worked with ASP Isotopes on isotope enrichment challenges [3] Strategic Initiatives - QLE is preparing for a spin-out anticipated in the second half of 2025, which involves building a senior leadership team to establish it as a standalone company [5] - The company has entered into a loan agreement with TerraPower for financing the construction of a uranium enrichment facility in South Africa [7] Technology and Market Potential - ASP Isotopes believes its Quantum Enrichment process can produce High Assay Low-Enriched Uranium (HALEU) at competitive prices, promoting the adoption of new nuclear energy [8] - The Nuclear Energy Institute estimates a potential HALEU supply demand of approximately 3,000 metric tons by 2035, with indications that actual demand may be higher [10] Future Energy Landscape - Global energy consumption is expected to double in the next 30 years, necessitating a zero increase in carbon emissions to meet 2050 climate goals [11] - Advanced nuclear fuels, particularly HALEU, will be essential for the operation of future small modular reactors [10][11]

Core Insights - ASP Isotopes Inc. has commenced the production of highly enriched Ytterbium-176, a critical material for oncology treatments, following the successful commissioning of its Quantum Enrichment facility in Pretoria, South Africa [3][4][5] - The company aims to achieve 99.75% enrichment for Ytterbium-176 and plans to offer it for commercial sale in 2025 [5][8] - ASP Isotopes is also planning to construct additional enrichment facilities for Nickel-64, Gadolinium-160, and Lithium-6/7 based on the success of the Ytterbium-176 facility [10][12] Company Developments - The Ytterbium-176 enrichment facility is the company's third in South Africa and utilizes a novel laser-based Quantum Enrichment method, which is believed to be more efficient and scalable than traditional methods [4][5] - The construction phase of the facility took only 8 months, significantly shorter than the anticipated 18 months, and the commissioning phase took 6 months [5] - The company has received considerable interest from customers in North America, Europe, and Asia for Ytterbium-176, indicating a strong demand for this isotope [9] Market Context - The beta-emitting radiopharmaceutical market, including drugs like Novartis' Pluvicto, is projected to exceed $15 billion annually in the next decade, with consensus forecasts for Pluvicto alone exceeding $4 billion [8] - There are significant supply-side challenges for essential radioisotopes, with reports of treatment delays due to drug availability [8][9] - ASP Isotopes aims to be one of the few suppliers of commercial quantities of Ytterbium-176 and similar isotopes in the Western world, addressing current supply chain issues [8][9] Future Plans - The company is in discussions with nuclear regulatory authorities for the authorization to construct HALEU uranium enrichment facilities using Quantum Enrichment technology in South Africa and other countries [2][16] - There is an anticipated demand for Lithium-6 and Lithium-7 for future nuclear fusion power plants and advanced nuclear reactors, with no current Western producers of Lithium-6 in commercial quantities [13][15] - The company believes its Quantum Enrichment process could produce HALEU at competitive prices, potentially accelerating the adoption of new nuclear energy solutions [14][15]